Age (years) | 61 (7) | 61 (7) |
Height (cm) | 170 (7) | 168 (7) |
Male (n) | 89 | 79 |
FEV1(l) | 1.42 (0.47) | 1.30 (0.38) |
FEV (% pred) | 46 (11) | 44 (10) |
FEV1/IVC (%) | 49 (13) | 47 (11) |
Airway reversibility (% of FEV1 pred) | 3.2 (2.7) | 2.9 (2.5) |
Pack years | 40 (25) | 43 (24) |
Smoker (current/ex) | 32/63 | 34/54 |
Cigarettes/day (n) | 17 (12) | 17 (11) |
Log10(IgE+1) (IU/ml) | 1.71 (0.59) | 1.67 (0.50) |
Regular use of (% of patients): | | |
Anticholinergics | 25 | 32 |
Short acting β2 agonists | 60 | 62 |
Theophylline | 56 | 53 |
Mucolytics | 33 | 40 |
Almitrine | 10 | 13 |
During the study: | | |
Exacerbations/year | 0.9 (0.9) | 1.0 (1.3) |
Drop outs (n) | 35 | 29 |
Reason for drop out (n): | | |
Worsening of the disease | 4 | 9 |
Adverse effects | 17 | 12 |
Other reasons | 14 | 8 |